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Dear Editor,
I thank Dr. Hurtado and Dr. Appell for their comment [1]
on the long-term results after transurethral injection of
ethylene vinyl alcohol [2].
We criticized the additional amount of injectable in the
study carried out by Hurtado and colleagues on the basis of
the data of the original European multicentre study; these
data have unfortunately never been published but showed a
dose-dependent increase of complications. This study was
performed in the late 1990s, and at that time the appropriate
amount of ethylene vinyl alcohol was unclear as only
animal data were available. The latter confirmed material
consistence and lack of migration. An interim analysis of
data showed a correlation of postoperative complications
and amount of injected material, which resulted in the
specific dose recommendations that were advised for the
used amount of ethylene vinyl alcohol by the manufacturer.
This is the background to our discussion of this point
quoting the study by Hurtado et al. [3].
I absolutely agree with Hurtado and Appell that the
difference in the proportion of naïve patients in their study
compared to ours can result in different outcomes; I am sure
that any kind of urethral scarring as in the quoted study
including male patients after prostatectomy [4] or previous
injections with permanent materials will make further
injectable treatment difficult and possibly increase the risk
for urethral erosion.
I do not consider our success rate of 42% as exception-
ally good for a surgical incontinence procedure; possibly it
was just by chance that we did not see urethral erosions in
our study of only 33 patients, which is indeed not a large
number.
I am not well informed of the reasons for withdrawal of
the substance but assume that any report of urethral erosion
after transurethral injection must be considered a serious
adverse event. I guess that complications, particularly after
so-called minimally invasive procedures, are often under-
reported.
We must be cautious using permanent injectables for
which there are no long-term data. This is the reason why
we implant new substances or devices for incontinence
under study conditions and after detailed patient informa-
tion only.
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